The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?

Larry Goldenberg, OBC, MD, FRCSC,* Alan So, MD, FRCSC,† Neil Fleshner, MD, MPH, FRCSC,§ Ricardo Rendon, MD,‡ Darrel Drachenberg, MD, FRCSC,** Mostafa Elhilali, MD, FRCSC‡‡

Abstract

Normal growth and function of the prostate are contingent on the reduction of testosterone to dihydrotestosterone (DHT) by 5-alpha reductase (5-AR) enzymes types 1 and 2. It has been theorized that an overabundance of DHT may be implicated in the pathogenesis of both benign prostatic hyperplasia (BPH) and prostate cancer. Inhibitors of 5-AR such as dutasteride and finasteride may therefore have an important role in the prevention and treatment of BPH and prostate cancer. Dutasteride provides greater suppression of DHT than finasteride, thereby underlying the hypothesis that inhibition of both type 1 and type 2 would provide correspondingly greater protection than inhibition of type 2 alone. We review the potential significance of the 5-AR inhibitors in reducing the risk of prostate cancer according to the basic biology of prostate disease.

Introduction

Opportunities for studying the molecular action of androgens emerged in the 1960s, when radioactive compounds suitable for experimentation were initially introduced. In 1968, Bruchovsky and Wilson and Anderson and Liao reported that dihydrotestosterone is the active intracellular form of testosterone, and receptors for dihydrotestosterone were demonstrated for the first time. Two isoforms of the enzyme have been identified: type 1, which is found in skin, prostatic epithelium and to a lesser extent in stroma, and type 2, which predominates in prostatic stromal tissue. Normal growth and function of the prostate are contingent on the reduction of testosterone to dihydrotestosterone (DHT) by 5-alpha reductase (5-AR).

Overabundance of DHT has been implicated in the pathogenesis of benign prostatic hyperplasia (BPH) and prostate cancer. Preventing DHT synthesis via 5-AR inhibition has been shown to have a remarkable effect on benign prostatic disease with low toxicity. Thus, there is much interest in the potential role for 5-AR inhibitors (5-ARIs) in the management of prostatic intraepithelial neoplasia (PIN) and the prevention of prostate cancer. This report reviews current knowledge about the role of androgens and the 5-AR system in prostate disease and highlights their significance in reducing the risk of prostate cancer.

Prostate dependence on androgens

Androgens play an essential role in prostatic development and function, but are also involved in prostate disease pathogenesis. Without androgens, the prostate would not develop and the gland would atrophy if androgen support was withdrawn.

The principal and functionally active androgen DHT is synthesized from testosterone by 5-AR types 1 and 2. This leads to a 5-fold higher concentration of DHT v. testosterone within the prostate cells, v. an 11-fold higher concentration of testosterone in the blood.

In a study by Wright and colleagues, Sprague-Dawley rats were castrated for 2 weeks to allow their prostates to fully regress and were then given testosterone implants of various sizes in the presence or absence of a 5-AR inhibitor. Dramatic increases in prostate weight were seen even at the lowest serum testosterone levels in the absence of 5-AR inhibition, while significantly higher serum testosterone levels were needed to achieve prostate growth in the
presence of 5-AR inhibition. The difference in potency of testosterone v. DHT in relation to prostate growth is small compared with intraprostatic androgen concentrations, but is much greater if serum testosterone levels are considered.

A critical question regarding androgen action is whether testosterone and DHT are responsible for regulating the expression of different androgen-response genes in the prostate. Experimental studies suggest that testosterone is more potent than DHT in stimulating the expression of many androgen-response genes in the regressed prostate. The expression of these androgen-response genes is likely to be associated with androgen-dependent and prostate-specific differentiation, including the very important preservation of the capacity of prostatic cells to undergo apoptosis, and less associated with stimulating proliferation during prostate growth. On the other hand, high levels of intracellular DHT result in cellular proliferation and delay in cellular differentiation, an important fact when considering treatment of early prostatic disease, or premalignant conditions with 5-AR inhibition.

5-ARs and prostate cancer development

5-AR2 has traditionally been viewed as the most clinically relevant of the 5-AR isoenzymes because of its high concentration in prostatic tissue and its greater affinity to bind testosterone than 5-AR1. However, more recently, 5-AR1 expression has also been shown to be increased in prostate cancer compared with normal and BPH tissue at both the messenger RNA (mRNA) level and at the protein level. Thomas and colleagues provide a review of this data. They and colleagues have shown that the expression of 5-AR1 mRNA was significantly increased (p < 0.05) in prostate cancer compared with normal and BPH tissue but that the level of 5-AR2 mRNA was not statistically different from that observed in normal prostate. By contrast, the increased expression of 5-AR1 mRNA in BPH tissue was not statistically different from that of type 2 in the same tissue. Similarly, Thomas and colleagues showed that 5-AR1 mRNA levels are increased, whereas 5-AR2 mRNA levels are decreased, in primary prostate cancer compared with normal and BPH tissues. Thomas and colleagues also showed by immunostaining that 5-AR1 is increased in adjacent benign tissues, low-grade prostate cancer and moderate-grade prostate cancer compared with that in BPH. 5-AR1 was even further increased in high-grade cancers compared with BPH, or low- and moderate-grade cancers (Figure 1). By contrast, staining for 5-AR2 was decreased in adjacent benign tissue, as well as in low- and moderate-grade cancers compared with that in BPH, and was increased in high-grade cancers compared with low-grade cancers (Figure 1). A recent study by Xu and colleagues reported that 5-AR2 enzymatic activity was more than 10-fold higher than 5-AR1 enzymatic activity in both normal rat ventral prostatic cells and normal human prostate tissue. However, prostate cancer cells from both humans and rats expressed low levels of 5-AR2, and enhanced levels of 5-AR1 activity compared with nonmalignant tissues. Thomas and colleagues have demonstrated that levels of both 5-AR1 and 5-AR2 are increased in localized high-v. low-grade prostate cancer and that the levels of 5-AR1 were higher in benign tissue adjacent to cancer than in BPH. The mean (+ SEM) area of moderate-to-high staining for 5-AR1 increased from 20.5% (3.7%) in low-grade cancers (Gleason score

![Fig. 1. Mean area of moderate- to high-intensity staining, as a percentage of total epithelial or tumour area, for 5-AR1 and 5-AR2 in benign prostatic hyperplasia (BPH), benign tissues adjacent to cancer (Adj. Ben.), and low-, moderate- or high-grade cancer. Reproduced with permission from the Journal of Urology.](image-url)
5-alpha reductase inhibitors in prostate pathophysiology

Results of a phase II, double-blind, placebo-controlled, comparative dose-ranging trial clearly showed that serum DHT suppression was significantly greater with dutasteride (94.7% ± 3.3% with 0.5 mg) than with finasteride (70.8 ± 18.3%, p < 0.001), and that the response to dutasteride was less variable. Serum DHT concentrations returned to within 20% of baseline values in only 4 weeks post-treatment in patients given finasteride, compared to 16 weeks in those given dutasteride (Figure 2). From the same study, Roehrborn and colleagues[17] reported greater than 90% DHT suppression in 85.4% of patients treated with dutasteride (0.5 mg) and in only 2.2% of patients treated with finasteride (5 mg). By comparison, greater than 70% DHT suppression was observed in 100% of the dutasteride-treated patients and in 49% of the finasteride-treated patients.[17,18] In another approach, Gleave and colleagues[19] showed that men who were treated with dutasteride (doses 0.5 mg daily or higher) for 4 months prior to radical prostatectomy had significantly lower intraprostatic DHT concentrations but had higher testosterone concentrations than in untreated prostatectomies. Furthermore, men who received dutasteride had lower tumour volumes, without significant changes in treatment alteration scores or atrophy, than those who received surgery alone.[19] Similarly, Iczkowski and colleagues[20] showed that in cancer tissues from men who received pre-surgical treatment with dutasteride compared with that from men treated with finasteride, tumour volume had decreased significantly (mean 15% v. 24%, p = 0.025), the percentage

![Fig. 2. Dual 5-alpha reductase inhibition results in greater serum dihydrotestosterone (DHT) suppression. Percentage changes from baseline in DHT over time are shown as arithmetic means. Data were derived from the Journal of Clinical Endocrinology and Metabolism.[9]](image-url)
of atrophic epithelium had increased ($p = 0.041$) and both the stroma/gland ratio and treatment alteration effect had doubled. The ability to induce phenotypic alterations in both the benign and neoplastic prostate suggest a potential chemopreventive role for dutasteride.\textsuperscript{20}

### Effects on serum PSA concentration

Prostate specific antigen (PSA) is a biomarker whose expression is governed by androgens, and whose serum concentration can be used in the detection of prostate cancer. That said, treatment with 5-ARIs such as finasteride or dutasteride results in decreased serum PSA concentrations, which may make the interpretation of the test difficult.\textsuperscript{21} In the randomized, double-blind, active-controlled Enlarged Prostate International Comparative Study (EPICS), dutasteride and finasteride treatment resulted in similar median PSA suppression of approximately 55% at 12 months (GlaxoSmithKline, data on file). Finasteride treatment in the PLESS trial resulted in a median change of 57% after 4 years.\textsuperscript{22} Marks and colleagues,\textsuperscript{23} in a review of 3 large-scale, phase III studies, reported that dutasteride treatment results in a median change in PSA of 66% at 4 years. Differences in PSA suppression between finasteride and dutasteride may reflect the impact of blocking 5-AR1 in prostate cells. That PSA is not reduced to zero implies ongoing binding of testosterone on the androgen receptor, which normally is much weaker than DHT binding,\textsuperscript{24} or the possible existence of a type 3 isoenzyme.\textsuperscript{25} The significance of these data is highlighted by the results of the Prostate Cancer Prevention Trial (PCPT), in which the overall decrease in prostate cancer cases associated with finasteride treatment was coupled with an increase in the number of high-grade prostate cancer cases.\textsuperscript{26} Thirty-seven percent of cancers in the finasteride group had a Gleason score of 7 to 10 compared with 22% in the placebo group, with the increase in high-grade cancers present mainly in the Gleason 8 to 10 range.\textsuperscript{26} It has been suggested that detection bias for high-grade tumours in patients treated with finasteride may help to explain these findings and that this may be due in part to improved specificity and sensitivity of detection of PSA and DRE under 5-ARI treatment.\textsuperscript{27} Finasteride inhibits only 5-AR2, resulting in a decrease in PSA of 50%. In low-grade cancer, the amount of 5-AR2 may still predominate; therefore, both finasteride and dutasteride should produce an adequate reduction in the level of PSA. By contrast, in high-grade cancers, levels of 5-AR1 and 5-AR2 are both increased\textsuperscript{11} so that finasteride will theoretically block progression of low-grade cancers but not high-grade cancers. This issue may be clarified with the release of the Reduction by DUtasteride of Prostate Cancer Events (REDUCE) study data.\textsuperscript{28}

### Influence of somatic 5-AR mutations

The identification and characterization of somatic 5-AR mutations in human prostate cancer tissue have implications both in the predisposition and in the progression of prostate cancer. Makridakis et al. reported that in about 60% of prostate tumours, somatic substitutions occur in the protein-coding region of the SRD5A2 gene, which encodes 5-AR. Approximately 20% of tumour samples had SRD5A2 mutations that significantly activated steroid androgen receptor, while only 7% had SRD5A2 mutations that reduced enzyme activity significantly. It is, therefore, possible that these genetic variants may play an important role in the development and progression of BPH and prostate cancer, and may help individualize cancer treatment and prevention through pharmacogenetic mechanisms.\textsuperscript{29} Further in vitro analysis showed that dutasteride was an efficient steroid 5-AR inhibitor for most of the enzyme variants, with the exception of P48R and F194L, and that dutasteride treatment would also be expected to result in lower pharmacogenetic variation in vivo than finasteride treatment.\textsuperscript{30}

### Castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC) remains a therapeutic challenge, and it has been hypothesized that dual 5-AR inhibition may be valuable in its management. Eggener and colleagues\textsuperscript{31} reported that a combination of dutasteride, but not finasteride, plus castration, achieved significantly greater reductions in LNCaP tumour growth in xenograft-bearing nude mice than castration alone ($p < 0.05$) and that dutasteride-treated mice were 3 to 5 times more likely to be alive 70 days following treatment than those treated with finasteride. Current data suggest that the androgen receptor is expressed and continues to mediate androgen signaling after failure of androgen deprivation therapy. Although hormone suppression treatment eliminates the detectable levels of testosterone in the blood, the levels in tissue remain high enough to stimulate androgen receptors and allow both survival of tumour cells and induction of resistance by overexp-
pression of the receptor. Locke and colleagues have shown that all enzymes necessary for androgen synthesis are expressed in prostate cancer tumours, and some seem to be up-regulated during CRPC progression, suggesting that de-novo synthesis may be a driving force behind castration resistance. A combination of androgen deprivation (goserelin with bicalutamide and/or ketoconazole) and dual inhibition (dutasteride) could inhibit tumour growth by reducing intracellular androgen synthesis, and this is currently being studied at the University of Washington.

Conclusions

The enzyme 5-AR, which reduces testosterone to DHT, exists in 2 forms: type 1 and type 2. Dutasteride inhibits both, whereas finasteride inhibits type 2 only. Available data show that dutasteride, in contrast to finasteride, provides greater suppression of DHT than finasteride, is able to shrink tumour volume quicker and more dramatically than finasteride, and is more effective against genetic variants of 5-AR than is finasteride. Thus, the dual inhibition of 5-AR may prove more useful in the treatment of BPH in reducing the risk of prostate cancer and in the treatment of CRPC. Full clinical investigations of these and other approaches to the inhibition of 5-AR are ongoing and results are greatly anticipated.

References


Correspondence: Dr. Larry Goldenberg, Diamond Healthcare Centre, 2775 Laurel Street Level 6, Vancouver, BC V5Z 1M9; l.gold@ubc.ca

We welcome your comments on the journal and on specific articles.

All letters will be considered for publication in the journal.

Send your letters to the Editor-in-Chief at journal@cua.org